Sorafenib therefore represents a pharmacological means to indirectly inhibit the expression and functions of NDRG1, and suggests that sorafenib may be combined with other NDRG1-based therapeutic interventions to achieve synergistic anti-tumor effects in advanced HCC patients with aggressive phenotypes. Here, NDRG1 is linked to hepatocellular carcinoma.